

May 9, 2012



Navidea Biopharmaceuticals Announces the Presentation of Data at Several Upcoming Scientific Meetings

- Clinical trial data from oncology and Alzheimer's disease product candidates to be presented -

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical studies investigating Lymphoseek® (Kit for the Preparation of Technetium Tc 99m Tilmanocept for Injection) in head and neck cancer, breast cancer, and melanoma and from Phase 1/Phase 2 clinical trials of its Alzheimer's Disease candidate, AZD4694, were accepted for presentation at several upcoming scientific and medical meetings in May. Details of the presentations are listed below.

Conference: **European Society for Therapeutic Radiology and Oncology**

Dates: May 9-13

Location: Barcelona, Spain

Author: 1. Frederick O. Cope, PhD; 2. Wendy L. Metz, PhD, Navidea Biopharmaceuticals

Presenter: Michael S. Blue, MD, Navidea Biopharmaceuticals

Presentation Titles:

1. *Tc99m Tilmanocept, A CD206 ILM Agent, Has >24 Hour Stability in Nodes and Concordance with Imaging in Breast Cancer*
2. *Correlation of Lymphoscintigraphy with Intraoperative Lymphatic Mapping in Phase 3 with Tc99m Tilmanocept in Breast Cancer and Melanoma*

Conference: **12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy**

Dates: May 9-12

Location: Stockholm, Sweden

Author: Zsolt Cselényi, AstraZeneca, Södertälje, Sweden

Presentation Title:

1. *Early clinical development of amyloid-beta specific PET radioligand [¹⁸F]AZD4694*

Conference: **Australasian Lymphology Association**

Dates: May 24-26

Location: Queensland, Australia

Author: Wendy L. Metz, PhD

Presentation Title:

1. *Estimation of intra-surgical sentinel lymph node mapping performance parameters of 99mTc-tilmanocept in melanoma and other solid tumors utilizing in vitro modeling with fluorescent Cy3-tilmanocept; alteration of mannose moiety configuration binding to human lymph node macrophages and the CD206 receptor*

Conference: **International Symposium on Sentinel Node Biopsy in Head and Neck Cancer**

Dates: May 24-25

Location: Amsterdam, the Netherlands

Author: Stephen Y. Lai, MD, PhD, FACS, University of Texas M.D. Anderson Cancer Center

Presentation Title:

1. *Detection of Sentinel Lymph Nodes in Cutaneous and Intraoral Head and Neck Squamous Cell Carcinoma with 99m-Tc-Tilmanocept: Clinical Experience at M.D. Anderson Cancer Center*

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek[®], AZD4694 and RIGScan[™] – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals, Inc.

Brent Larson, 614-822-2330

Sr. VP & CFO

Source: Navidea Biopharmaceuticals, Inc.